Synthaverse Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Synthaverse.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth42.2%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

No updates

Recent updates

Synthaverse (WSE:SVE) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Nov 28
Synthaverse (WSE:SVE) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Optimistic Investors Push Synthaverse S.A. (WSE:SVE) Shares Up 32% But Growth Is Lacking

Apr 20
Optimistic Investors Push Synthaverse S.A. (WSE:SVE) Shares Up 32% But Growth Is Lacking

Why Synthaverse's (WSE:SVE) Soft Earnings Are Just The Beginning Of Its Problems

Apr 18
Why Synthaverse's (WSE:SVE) Soft Earnings Are Just The Beginning Of Its Problems

BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) Seems To Use Debt Quite Sensibly

Oct 14
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) Seems To Use Debt Quite Sensibly

More Unpleasant Surprises Could Be In Store For BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.'s (WSE:BML) Shares After Tumbling 48%

Nov 29
More Unpleasant Surprises Could Be In Store For BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.'s (WSE:BML) Shares After Tumbling 48%

We Think You Should Be Aware Of Some Concerning Factors In BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek's (WSE:BML) Earnings

Nov 16
We Think You Should Be Aware Of Some Concerning Factors In BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek's (WSE:BML) Earnings

Does BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) Deserve A Spot On Your Watchlist?

May 02
Does BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) Deserve A Spot On Your Watchlist?

Is BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) A Risky Investment?

Mar 08
Is BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) A Risky Investment?

What Percentage Of BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. (WSE:BML) Shares Do Insiders Own?

Jan 29
What Percentage Of BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. (WSE:BML) Shares Do Insiders Own?

Should Weakness in BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.'s (WSE:BML) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

Jan 03
Should Weakness in BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.'s (WSE:BML) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) Takes On Some Risk With Its Use Of Debt

Dec 07
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) Takes On Some Risk With Its Use Of Debt

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Synthaverse has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

WSE:SVE - Analysts future estimates and past financials data (PLN Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
9/30/2024634-5815N/A
6/30/2024572-1026N/A
3/31/2024614-1181N/A
12/31/2023595-118-5N/A
9/30/2023533-97-6N/A
6/30/2023587-68-2N/A
3/31/2023547-432N/A
12/31/2022506-343N/A
9/30/2022517-300N/A
6/30/2022444-26-6N/A
3/31/2022445-19-4N/A
12/31/2021414-22-3N/A
9/30/2021395-111N/A
6/30/2021405-14N/A
3/31/2021352-40N/A
12/31/2020404-20N/A
9/30/2020412-4-2N/A
6/30/202040334N/A
3/31/202040345N/A
12/31/201939278N/A
9/30/201935-29810N/A
6/30/201936-3113N/A
3/31/201935-3247N/A
12/31/201832-32-3-1N/A
9/30/20183110-2-5N/A
6/30/20183111N/A-2N/A
3/31/2018301N/A-2N/A
12/31/2017311N/A4N/A
9/30/201731-23N/A31N/A
6/30/201732-27N/A30N/A
3/31/201737-26N/A10N/A
12/31/201636-26N/A16N/A
9/30/201646-48N/A-4N/A
6/30/201645-45N/A-15N/A
3/31/201647-35N/A5N/A
12/31/201543-37N/A-3N/A
9/30/201538-2N/A-5N/A
6/30/201536-2N/A2N/A
3/31/201531-2N/A1N/A
12/31/2014340N/A-1N/A
9/30/201428-3N/A-9N/A
6/30/2014290N/A-7N/A
3/31/2014310N/A-7N/A
12/31/2013331N/A-7N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if SVE's forecast earnings growth is above the savings rate (4.1%).

Earnings vs Market: Insufficient data to determine if SVE's earnings are forecast to grow faster than the Polish market

High Growth Earnings: Insufficient data to determine if SVE's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if SVE's revenue is forecast to grow faster than the Polish market.

High Growth Revenue: Insufficient data to determine if SVE's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if SVE's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/27 10:03
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Synthaverse S.A. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution